BSM Biotech Holding Launches Operations to Build Next Generation of Breakthrough Biotech Companies

Biotech venture builder focuses on identifying and developing first-in-class therapeutic innovations, exiting at IND stage

 
GRAINAU, Germany, April 02, 2026 / Biotech Newswire / -- BSM Biotech Holding GmbH ("BSM"), a newly launched biotech venture builder, today announced that it has formally commenced operations and is emerging from stealth mode. BSM aims to translate cutting-edge scientific discoveries into high-value therapeutic assets by founding and building new biotechnology companies around breakthrough innovations primarily sourced from leading academic institutions.
 
BSM’s strategy focuses on identifying promising molecular targets and therapeutic approaches with the potential to address major unmet medical needs, particularly in oncology and other severe diseases. Through a rigorous scientific and commercial assessment process, BSM selects projects with the potential to become first-in-class drugs and advances them through early development towards an Investigational New Drug (IND)-ready stage, where pharmaceutical companies frequently acquire innovative assets.
 
“Many of the most transformative medical innovations originate in academia, but they lack the resources and structured development required to reach their full potential,” said Dr Joachim M. Greuel, CEO of BSM Biotech Holding. “BSM was founded to bridge this gap. We systematically identify exceptional scientific discoveries, validate their commercial and therapeutic potential, and build focused biotech companies around them.”
 
Over the coming years, BSM intends to build a diversified portfolio of early-stage biotech companies, each focused on a specific therapeutic innovation. By combining disciplined project selection, capital-efficient development strategies and early exit opportunities, BSM seeks to generate attractive returns for investors while accelerating the development of transformative medicines.
 
A core element of BSM’s model is its collaboration with BioScience Valuation (BSV), a specialised life sciences advisory firm with over 25 years' experience in evaluating biotechnology investments. Through this partnership, BSM gains access to extensive scientific, commercial and financial expertise, supporting evidence-based decision-making and reducing development risk.
 
Additionally, BSM integrates AI-supported molecular target identification and validation approaches, enabling the company to identify promising new drug targets and prioritise development opportunities with the greatest potential for medical and commercial impact.
 
“BSM is unique because it combines deep scientific insight, advanced analytical capabilities, and a venture-builder model designed specifically for biotechnology,” Greuel added.
 
Dr. Dirk Kreder, CFO, commented: “By focusing on early development and exiting at the Investigational New Drug (IND) stage, we aim to capture the exponential value creation that occurs when innovative discoveries are translated into drug candidates ready for clinical trials.”
 
Dr. Sabine Bernotat-Danielowski, CDO, and Dr. Michael Ruppert, CBO, complete BSM’s leadership team that has decades of experience in pharmaceutical R&D, building technology companies, deal making and evaluating life-science investments. The team has collectively participated in the development, commercialisation and valuation of numerous therapeutic programs across major global markets.
 
With its launch, BSM will begin actively sourcing scientific discoveries from universities, research institutions, and early-stage innovation ecosystems worldwide. The company expects to found and develop multiple new biotech ventures over the coming years.
 
Semantic keywords: BSM Biotech Holding; biotech venture builder; biotechnology companies; scientific discoveries; academic institutions; research institutions; molecular targets; therapeutic approaches; first-in-class drugs; therapeutic innovations; unmet medical needs; oncology; early development; Investigational New Drug; IND-ready stage; pharmaceutical companies; acquisition; AI-supported molecular target identification
 
About BSM Biotech Holding
BSM Biotech Holding GmbH is a biotech venture builder that focuses on translating innovative scientific discoveries into valuable therapeutic assets. The company sources breakthrough research primarily from leading academic institutions, establishes project-focused biotech companies and advances them through early development towards Investigational New Drug (IND) readiness. BSM’s strategy combines rigorous scientific and commercial evaluation, AI-supported target selection and capital-efficient development, creating value for investors while accelerating the development of innovative medicines.
 
Contacts
BSM Biotech Holding GmbH
Dr Joachim M Greuel, MBA
CEO
j.greuel@biotech-holding.com
Dr Dirk Kreder, MBA
CFO
d.kreder@biotech-holding.com
www.biotech-holding.com
Source: Biotech Newswire